2023 World Conference on Lung Cancer (Posters)-P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome

P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome - PDF(Abstract)

Back to course

Pdf Summary

This study focuses on the immune response signatures in resected non-small cell lung cancer (NSCLC) tumors and their correlation with clinical outcomes. The researchers hypothesized that the immune profiles in formalin-fixed paraffin-embedded (FFPE) tumors can provide insight into the antitumor capability of the patient's immune system and predict the risk of recurrence (REC) or development of a second primary tumor (2P).<br /><br />Using the NanoString GeoMx Digital Spatial Profiler (GeoMxDSP), the researchers analyzed intratumoral immuno-RNA and protein abundance in different regions of interest (ROI) within the tumors. They identified inflamed/hot and non-inflamed/cold tumor regions based on morphology. Tumor and immune cell populations were then profiled using gene expression panels.<br /><br />Statistical analyses were conducted to identify immuno biomarkers predicting REC and/or 2P. Cox proportional hazard (PH) ratio model analysis was used, and false discovery rate (FDR) correction was applied for multiple testing. The results showed that certain biomarkers, including CXCL10, CXCR6, PDCD1LG2, TIGIT, and MKI67, were predictive of REC or 2P.<br /><br />The study included 38 NSCLC patients with T1-2N0M0 stage tumors. Among the top 10 significant immuno-RNAs identified, five were identical and showed similar predictive effects for 2P, while one biomarker predicted REC. Covariate adjustment in the analysis removed eight markers as significant predictors.<br /><br />Overall, the study demonstrates the feasibility of analyzing the immune milieu of a patient's tumor and its correlation with REC or 2P. Further validation studies and analysis of functional proteins are ongoing. This research has implications for understanding the role of the immune system in early-stage NSCLC and potentially guiding personalized treatment decisions.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

immune response signatures

NSCLC tumors

clinical outcomes

FFPE tumors

antitumor capability

immune system

risk of recurrence

gene expression panels

immuno biomarkers

personalized treatment decisions